glp 1 agonist in ckd GLP-1 agonists the treatment of chronic kidney disease in type 2 diabetes and obesity Potential renoprotective effects of GLP1

The relative contribution of each receptor target (GIPR, GLP-1R, GCGR) to the effects reported in human trials remains a mechanistic priority, because receptor-selective dissection studies in humans have not appeared in the primary literature

10.1016/j.rbmo.2014.02.004 18

Lab Tests & Documentation Certificates of Analysis and lot documentation

Additional Discount: First order

Standard reconstitution (most common) Add 2ml of bacteriostatic water to 5mg vial This creates: 2,500mcg per ml (2.5mcg per unit on insulin syringe) Easy math : 250mcg dose = 0.10ml = 10 units on syringe 350mcg dose = 0.14ml = 14 units 500mcg dose = 0.20ml = 20 units Most people prefer this concentration for easy dosing